Decompensated Cirrhosis and GLP-1 Receptor Agonist Contraindication

Introduction to Decompensated Cirrhosis

The European Association for the Study of the Liver (EASL) recommends that GLP-1 receptor agonists should be avoided in decompensated cirrhosis because they are only approved and studied for use in Child-Pugh class A (compensated) cirrhosis, and insulin is the only evidence-based treatment option for patients with decompensated liver disease 1, 2, 3

Decompensated cirrhosis represents advanced liver failure characterized by clinical manifestations including ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, or jaundice 3
Child-Pugh class B or C classification indicates significant hepatic dysfunction 1, 2
Extreme metabolic instability with unpredictable glucose fluctuations and altered drug metabolism 3

The EASL-EASD-EASO guidelines recommend that GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) can only be used in Child-Pugh class A cirrhosis 1, 2
No safety or efficacy data exist for GLP-1 RAs in decompensated cirrhosis 1, 3
Insulin is the only evidence-based option for decompensated cirrhosis and must be initiated in a hospital setting due to extreme glucose variability 3

For no cirrhosis or compensated cirrhosis (Child-Pugh A), the first-line treatment is GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) 1, 2
For Child-Pugh B cirrhosis, the first-line treatment is SGLT2 inhibitors (can be used in Child-Pugh B) 1, 4
For decompensated cirrhosis (Child-Pugh C or any decompensation event), the only option is insulin therapy, initiated in a hospital setting 1, 3

Do not continue GLP-1 RAs if decompensation develops, and immediately discontinue if ascites, encephalopathy, variceal bleeding, or jaundice occurs 3
Do not use GLP-1 RAs for weight loss in cirrhotic patients, as rapid weight loss can precipitate decompensation even in previously compensated cirrhosis 1, 3
Do not rely on HbA1c in decompensated cirrhosis, and use point-of-care glucose monitoring instead due to altered red blood cell turnover 3
Monitor renal function closely, as GLP-1 RAs can cause acute kidney injury through GI side effects and dehydration, and hepatorenal syndrome risk is amplified in cirrhotic patients 3